Disruption of transcriptionally active Stat3 dimers with non-phosphorylated, salicylic acid-based small molecules: potent in vitro and tumor cell activities.
about
Targeting SH2 domains in breast cancerSignal transducer and activator of transcription 3 (STAT3) inhibitor, S3I-201, acts as a potent and non-selective alkylating agentSTAT inhibitors for cancer therapy.A phosphopeptide mimetic prodrug targeting the SH2 domain of Stat3 inhibits tumor growth and angiogenesis.Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domainCoordination complex SH2 domain proteomimetics: an alternative approach to disrupting oncogenic protein-protein interactions.Changes in signal transducer and activator of transcription 3 (STAT3) dynamics induced by complexation with pharmacological inhibitors of Src homology 2 (SH2) domain dimerization.Progress towards the development of SH2 domain inhibitors.Development of new N-Arylbenzamides as STAT3 Dimerization Inhibitors.Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemiaA novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processesAntagonism of the Stat3-Stat3 protein dimer with salicylic acid based small molecules.Aberrant activation of signal transducer and activator of transcription-3 (STAT3) signaling in endometriosisA potent and selective inhibitor for the UBLCP1 proteasome phosphatase.A complex task? Direct modulation of transcription factors with small molecules.Potent and selective phosphopeptide mimetic prodrugs targeted to the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3.An activatable multimodal/multifunctional nanoprobe for direct imaging of intracellular drug delivery.Applying Small Molecule Signal Transducer and Activator of Transcription-3 (STAT3) Protein Inhibitors as Pancreatic Cancer TherapeuticsStructure-Activity Studies of Phosphopeptidomimetic Prodrugs Targeting the Src Homology 2 (SH2) Domain of Signal Transducer and Activator of Transcription 3 (Stat3).Signal transducer and activator of transcription 3 inhibitors: a patent review.Signal transducer and activator of transcription 3 (STAT3): a promising target for anticancer therapy.Extolling the benefits of molecular therapeutic lipidation.Novel inhibitors of signal transducer and activator of transcription 3 signaling pathway: an update on the recent patent literature.Current and future intratumoral targeted treatment for pancreatic cancer.A STAT inhibitor patent review: progress since 2011.Methanethiosulfonate derivatives as ligands of the STAT3-SH2 domain.Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)-Resistant CML Lines While Circumventing Pharmacokinetic LiabilitiesCrispene E, a cis-clerodane diterpene inhibits STAT3 dimerization in breast cancer cells.Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway.Artificially induced protein-membrane anchorage with cholesterol-based recognition agents as a new therapeutic concept.Design, synthesis, and in vitro characterization of novel hybrid peptidomimetic inhibitors of STAT3 proteinPotent Targeting of the STAT3 Protein in Brain Cancer Stem Cells: A Promising Route for Treating Glioblastoma.Enhanced miR-210 expression promotes the pathogenesis of endometriosis through activation of signal transducer and activator of transcription 3.Identification of Bidentate Salicylic Acid Inhibitors of PTP1B.Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, metastasis and STAT3 target gene expression in vivo.A new synthetic derivative of cryptotanshinone KYZ3 as STAT3 inhibitor for triple-negative breast cancer therapy
P2860
Q27014674-A5CC324D-B6A3-4982-970A-D4D7B3E54772Q28829622-5C2683CC-B486-4D11-9F65-2EDBE7A1026DQ33644206-4395DECB-C0DA-426B-981C-AC5636FF0FCAQ33661939-7B1C28AF-17F9-4FA1-B617-5CC97254B4F6Q33970769-D1402594-7475-49D2-A4BC-BA4B268D64D8Q34022050-F12E7F1E-72F4-4CCC-97C4-79996E142516Q34552575-A4FF0200-7E5E-4C30-B109-D64635B72BF9Q34581878-8ABC7B44-2320-4F91-8C98-266AE24B48FDQ35000997-150A5FE7-32EA-41FD-87B0-AB6ABE2BAFCFQ35102414-E966897A-9576-45EE-9DB4-E57326F4B3D5Q35282743-F81B7C74-D753-443B-A019-39197DF911A4Q35329489-7A54277F-CBBE-4B0D-A42C-4B2EAF0D9338Q35449469-C9AD5B6F-9DA4-4939-AA8D-C6B0AABCB716Q35613113-8796B11A-7775-400B-B338-49609A0BD06CQ35642431-86362225-3A4B-4186-9293-E4CBB4277CFCQ35869426-201275A1-135B-45C0-B221-A6787F2C2AA0Q35890042-0553249E-8479-4125-90A5-BF8BA57629C0Q36918125-49FC2C80-F4F0-44EB-B465-18685D4493F4Q37683068-69683A53-09DC-4822-AD17-ACDD145579FDQ37813134-023FA365-2E6E-4922-B1FE-E64C1451D752Q37869903-214BB7BC-0FA3-49E9-892B-50915C01C051Q38114781-B4F394D8-C750-4D49-87C0-5B8F1C8A5EFCQ38179031-C7DAC592-4E9D-44D5-9C3E-DCAA18A274E6Q38261961-5F12F488-5047-4CF2-9D5D-877161BC12BCQ38591166-DD2706A8-6F4D-4B75-B076-9DFF8B46E878Q38720827-58D7D5B9-3BD8-4338-9E96-02069C1AD7A7Q38782370-C72CA410-4519-431C-8660-25E1376CC2BEQ38905585-1D76C884-46D5-4AD1-8D95-A54D3A0B450EQ39159381-8E53919A-EABC-4434-8869-B898CE35646FQ39514656-F29AE8C1-858F-476F-9E69-36DF38FB2E13Q39610489-B1F92460-A188-4F1D-BA91-E4CA5B659358Q39778880-A087313A-CA34-42B7-84B7-B783B53BC303Q41680433-22175E5D-19BA-4267-9CB2-A1D087E6FC84Q43242949-D003DAB1-0FEB-4086-B095-8597A542A349Q50963721-6B85BFF7-BC05-461E-A7CA-698E13F8F513Q58110122-1180DA08-9F3F-45C6-9015-E7B273F6062A
P2860
Disruption of transcriptionally active Stat3 dimers with non-phosphorylated, salicylic acid-based small molecules: potent in vitro and tumor cell activities.
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Disruption of transcriptionall ...... tro and tumor cell activities.
@ast
Disruption of transcriptionall ...... tro and tumor cell activities.
@en
type
label
Disruption of transcriptionall ...... tro and tumor cell activities.
@ast
Disruption of transcriptionall ...... tro and tumor cell activities.
@en
prefLabel
Disruption of transcriptionall ...... tro and tumor cell activities.
@ast
Disruption of transcriptionall ...... tro and tumor cell activities.
@en
P2093
P2860
P356
P1433
P1476
Disruption of transcriptionall ...... itro and tumor cell activities
@en
P2093
Brent D G Page
Jagdeep Singh
James Turkson
Patrick T Gunning
Peibin Yue
Steven Fletcher
Sumaiya Sharmeen
Vijay M Shahani
Xiaolei Zhang
P2860
P304
P356
10.1002/CBIC.200900172
P577
2009-08-01T00:00:00Z